{"id":"ner1006-1-day-morning-split-dosing","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Abdominal distension"},{"rate":null,"effect":"Dehydration"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NER1006 is a polyethylene glycol (PEG)-based solution that draws water into the intestinal lumen through osmotic action, promoting bowel evacuation. The 1-day morning split-dosing regimen is designed to improve patient tolerability and compliance by reducing the total volume required and concentrating the dose into a shorter timeframe compared to traditional 2-day bowel preparation protocols.","oneSentence":"NER1006 is a bowel cleansing agent that works as an osmotic laxative to purge the colon of fecal matter in preparation for colonoscopy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:23:00.520Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bowel cleansing prior to colonoscopy"}]},"trialDetails":[{"nctId":"NCT05174845","phase":"","title":"Real Word Evidence With 1L Polyethylene Glycol (PEG)+ Ascorbic Acid in Iberia","status":"COMPLETED","sponsor":"Norgine","startDate":"2021-10-01","conditions":"Colon Cancer, Colon Disease, Colon Cleansing","enrollment":13393},{"nctId":"NCT04708366","phase":"PHASE4","title":"Colon Cleansing Efficacy With 1L vs. 2L vs. 4L-PEG for Colonoscopy Among Inpatients","status":"UNKNOWN","sponsor":"University of Bologna","startDate":"2021-02-01","conditions":"Colon Disease","enrollment":846},{"nctId":"NCT02273141","phase":"PHASE3","title":"Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus a Sodium Picosulfate and Magnesium Salt Solution Using Day Before-Only Dosing Regimen in Adults.","status":"COMPLETED","sponsor":"Norgine","startDate":"2014-11","conditions":"Colorectal Cancer, Colorectal Carcinoma, Colon Cleansing","enrollment":515},{"nctId":"NCT02273167","phase":"PHASE3","title":"Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus MOVIPREP® Using 2-Day Split-Dosing and 1-Day Morning Split-Dosing Regimen in Adults.","status":"COMPLETED","sponsor":"Norgine","startDate":"2014-10","conditions":"Colorectal Cancer, Colorectal Carcinoma, Colon Cleansing","enrollment":849}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"NER1006,1-Day Morning Split-Dosing","genericName":"NER1006,1-Day Morning Split-Dosing","companyName":"Norgine","companyId":"norgine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NER1006 is a vaccine component that induces an immune response. It is being studied in a clinical trial for various colon-related conditions, including colon cancer and colorectal carcinoma, in combination with 1L PEG + ascorbic acid.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}